Skip to content

Observational study for CardioCel

European Registry Program for the Use of CardioCel in Cardiac Septal Defects, and Valve and Annulus Repair

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON26419
Enrollment
200
Registered
2017-04-12
Start date
2017-04-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring repair of valves and annulus and cardiac septal defects including atrial septal defects, ventricular septal defects and atrioventricular defects.

Interventions

None listed

Sponsors

Admedus Regen Pty Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients requiring repair of valves and annulus and cardiac septal defects including atrial septal defects, ventricular septal defects and atrioventricular defects. The majority of participating subjects will be paediatrics, since the indication concerns congenital cardiac defects.

Exclusion criteria

Exclusion criteria: This Registry Program does not focus on patients with injured myocardial tissue.

Design outcomes

Primary

MeasureTime frame
The primary endpoints of the Registry Program are: •Occurrence of device related safety events, including unexpected or rare events •Device performance, as documented by interpretation of echocardiography: oDesired haemodynamics achieved oPatch dehiscence oPatch thickening oPatch retraction The secondary endpoint of the Registry Program is user satisfaction as evaluated during implantation surgery by the surgeon.

Contacts

Public ContactAnnelies van Mourik
A.vanMourik@factory-cro.com+31 229 2727 (extensie 110)

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)